UTIBRON NEOHALER
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $3,017 | 15 | 0 |
| 2021 | $2,263 | 15 | 0 |
| 2020 | $56,251 | 3,453 | 1,574 |
| 2019 | $395.12 | 22 | 20 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $56,646 | 3,475 | 91.5% |
| Unspecified | $5,279 | 30 | 8.5% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTI CENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY 2 PERIOD CROSS OVER AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF INDACATEROL AND OR GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONA | Novartis Pharmaceuticals Corporation | $3,017 | 0 |
| A MULTI CENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY 2 PERIOD CROSS OVER AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF INDACATEROL AND OR GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Novartis Pharmaceuticals Corporation | $2,263 | 0 |
Top Doctors Receiving Payments for UTIBRON NEOHALER — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , D.O | Pulmonary Disease | Rochester Hills, MI | $145.25 | 9 |
| , MD | Family Medicine | Kansas City, MO | $144.91 | 8 |
| , MD | Pulmonary Disease | Sherman, TX | $144.55 | 14 |
| , M.D | Critical Care Medicine | Seaford, DE | $141.13 | 8 |
| , MD, FCCP | Pulmonary Disease | South Boston, VA | $140.45 | 11 |
| , MD, FCCP | Critical Care Medicine | South Boston, VA | $140.45 | 11 |
| , D.O | Addiction Medicine | Hanover, PA | $137.26 | 7 |
| , MD | Internal Medicine | Somerset, KY | $136.97 | 11 |
| , MD | Pulmonary Disease | Rome, GA | $134.99 | 8 |
| , MD | Critical Care Medicine | Glastonbury, CT | $133.92 | 9 |
| , M.D | Family Medicine | Yonkers, NY | $133.64 | 7 |
| , M.D | Pulmonary Disease | Ottawa, KS | $133.62 | 9 |
| , M.D | Allergy & Immunology | Somerset, KY | $131.63 | 8 |
| , M.D | Pulmonary Disease | Bristol, TN | $131.28 | 10 |
| , MD | Critical Care Medicine | Bristol, TN | $131.28 | 10 |
| , MD | Internal Medicine | Terre Haute, IN | $131.27 | 9 |
| , M.D | Pulmonary Disease | Johnson City, TN | $129.76 | 7 |
| , M.D | Internal Medicine | Johnson City, TN | $129.76 | 7 |
| , MD | Pulmonary Disease | Lake Charles, LA | $128.34 | 7 |
| , DO | Sleep Medicine | Rome, GA | $127.95 | 8 |
| , MD | Pulmonary Disease | Garden City, NY | $127.49 | 6 |
| , MD | Critical Care Medicine | Knoxville, TN | $126.73 | 6 |
| , MD | Pulmonary Disease | New York, NY | $123.79 | 6 |
| , MD | Internal Medicine | Chicago, IL | $122.18 | 9 |
| , DO | Pulmonary Disease | Rochester Hills, MI | $120.98 | 7 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $61,925
- Total Doctors 1,592
- Transactions 3,505
About UTIBRON NEOHALER
UTIBRON NEOHALER is a drug associated with $61,925 in payments to 1,592 healthcare providers, recorded across 3,505 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..
Payment data is available from 2019 to 2022. In 2022, $3,017 was paid across 15 transactions to 0 doctors.
The most common payment nature for UTIBRON NEOHALER is "Food and Beverage" ($56,646, 91.5% of total).
UTIBRON NEOHALER is associated with 2 research studies, including "A MULTI CENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY 2 PERIOD CROSS OVER AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF INDACATEROL AND OR GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONA" ($3,017).